People ask this question at very specific moments: they are stopping treatment, they have surgery scheduled, they are planning a pregnancy, or a side effect has not settled. The answer starts with one number.
Quick Answer
As of September 26, 2026, semaglutide has an elimination half-life of about one week in the prescribing information for approved semaglutide products. Medications are generally considered cleared after roughly five half-lives, so semaglutide takes about five weeks to leave the body after a final dose, and the labeling of some approved products gives a somewhat longer window depending on the product and dose. That is an average from pharmacokinetic studies rather than a promise for any one person, and it is also why the injections are spaced as far apart as the label directs. Compounded medications are not FDA-approved as final products.
What a One-Week Half-Life Actually Means
Half-life is the time it takes for the amount of a drug in the body to fall by half. It is the single most useful number for understanding how a medication behaves, and it explains three things patients notice.
Why the injection is weekly. A medication that leaves the body in hours has to be taken daily or more often. One that halves over a week can be given once a week and still hold a steady level. The dosing schedule is a consequence of the chemistry, not a marketing choice.
Why the first month feels different from the fourth. With any medication given repeatedly, levels climb until the amount leaving each week matches the amount going in. For semaglutide that plateau, called steady state, arrives after roughly four to five weeks on a given dose. It is why the same dose can feel different in week two and week eight.
Why missing one dose does not reset anything. After a skipped week, most of the previous dose is still present. What to do about a missed dose is a question for the prescriber, not for arithmetic, but the medication is not gone.
Clearance Timeline After a Final Dose
| Time since last dose | Roughly how much remains |
|---|---|
| 1 week | about half |
| 2 weeks | about a quarter |
| 3 weeks | about an eighth |
| 4 weeks | about a sixteenth |
| 5 weeks | generally considered cleared |
This is the standard five-half-lives arithmetic, and it is an approximation for a typical adult. Real elimination varies from person to person, and the approved labeling reports population averages rather than a result for any one patient. Anyone who needs a precise answer for a medical reason should get it from their own clinician, who knows their history.
The Three Situations Behind This Question
Stopping treatment
Because levels fall gradually, people often describe appetite returning over weeks rather than overnight. Tirzepatide behaves differently here, and how long tirzepatide stays in your system sets the two side by side. That gradual return is the physiology of the medication leaving, not a sign that anything has gone wrong.
Two honest points. First, stopping is a decision worth making with the clinician who prescribed the medication, not alone, because there are usually options short of stopping entirely. Second, weight regain after stopping GLP-1 treatment is common and well documented in the medical literature; a plan for what comes next belongs in that same conversation.
Surgery or a procedure with sedation
Tell your surgical and anesthesia team that you take a GLP-1 medication, and tell them early rather than on the day. These medications slow stomach emptying, which is directly relevant to anesthesia safety, and professional anesthesiology societies have issued guidance on managing GLP-1 medications around procedures. That guidance has been revised as evidence accumulated, which is exactly why the instruction to follow should come from your own care team rather than from an article.
Pregnancy, or planning one
The prescribing information for approved semaglutide products advises stopping the medication a substantial period before a planned pregnancy, specifically because it clears so slowly. The interval is in the labeling, and the decision belongs with your clinician. If you are pregnant, may be pregnant, or are planning to be, tell your prescriber promptly rather than waiting for the next scheduled contact.
Does Compounded Semaglutide Behave Differently?
The pharmacokinetic data above comes from studies of approved semaglutide products. Compounded semaglutide contains semaglutide but is a distinct, patient-specific preparation that is not FDA-approved as a finished drug product, and formulations differ between pharmacies. Anyone with a specific question about a compounded preparation they have been dispensed should ask the prescribing clinician and the dispensing pharmacy, who know what was actually prepared.
The Bottom Line
About one week to fall by half, about five weeks, sometimes somewhat longer, to clear. That single fact answers most of what people are really asking: why dosing is weekly, why effects fade gradually rather than abruptly, and why surgery and pregnancy planning need lead time and a conversation with a clinician. Averages describe populations; your prescriber is the one who can speak to you.
Related guides
What the primary sources say
- DailyMed, U.S. National Library of Medicine, OZEMPIC (semaglutide) injection: prescribing information, section 12.3 Pharmacokinetics (accessed September 26, 2026): "With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 weeks after the last dose."
- DailyMed, U.S. National Library of Medicine, WEGOVY (semaglutide) injection and tablets: prescribing information, section 12.3 Pharmacokinetics (accessed September 26, 2026): "With an elimination half-life of approximately 1 week, semaglutide will be present in the circulation for about 5 to 7 weeks after the last injectable dose"
- DailyMed, U.S. National Library of Medicine, RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information, section 12.3 Pharmacokinetics (accessed September 26, 2026): "Semaglutide is present in the circulation for about five weeks after the last semaglutide tablet dose."
- MedlinePlus, U.S. National Library of Medicine, Semaglutide Injection: MedlinePlus Drug Information (accessed September 26, 2026; two consecutive items from the precautions list): "Your doctor will tell you to stop using semaglutide injection for 2 months before a planned pregnancy. if you are having surgery, including dental surgery, tell the doctor or dentist that you are using semaglutide injection."
- U.S. Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (accessed September 26, 2026): "compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed."
This article is for informational purposes only and does not constitute medical advice. Do not start, stop, or change any medication based on this page. Always consult the clinician who prescribed your medication. Compounded medications are not FDA-approved as finished drug products. Individual response varies.
Frequently Asked Questions
How long does semaglutide stay in your system?
The prescribing information for approved semaglutide products gives an elimination half-life of about one week. A medication is generally considered cleared after roughly five half-lives, which puts full clearance at about five weeks or somewhat longer after the final dose, depending on the product and dose. That is an average from pharmacokinetic studies, not a promise about any individual, and the clinician who prescribed the medication is the one who can say how it applies to you. The same slow elimination is why semaglutide is dosed once weekly rather than daily.
What is the half-life of semaglutide?
About one week, according to the prescribing information for approved semaglutide products. Half-life means the time it takes for the amount in the body to fall by half. It also explains why levels keep rising for the first month or so of treatment before leveling off, and why a missed dose does not empty the system.
How long do side effects last after stopping semaglutide?
Because the medication leaves slowly, effects generally fade gradually rather than stopping the day a dose is skipped. Some people describe appetite returning over several weeks as levels fall. Side effects that persist, worsen, or are severe are a reason to contact a clinician rather than wait them out, and stopping treatment is itself a decision worth making with the clinician who prescribed it rather than alone.
Do I need to stop semaglutide before surgery?
That is a decision for your surgical and anesthesia team, and the single most important thing you can do is tell them you take a GLP-1 medication well before the procedure. Professional anesthesiology societies have issued guidance on GLP-1 medications around anesthesia, because these medications slow stomach emptying, which matters for procedures requiring sedation. The guidance has been revised as evidence developed, so follow the instructions your own care team gives you rather than a timeline you read online.
How long should semaglutide be out of my system before pregnancy?
The prescribing information for approved semaglutide products advises discontinuing the medication a substantial period before a planned pregnancy, precisely because it clears so slowly. The specific interval is in the labeling and the decision belongs with your clinician, who knows your history and your plans. If you are pregnant, think you may be pregnant, or are planning to become pregnant, tell your prescriber promptly rather than waiting for a scheduled visit.
Is the half-life the same for Ozempic, Wegovy, and the semaglutide tablet?
Yes, according to the prescribing information. The labels for the injectable products and for the oral tablet all describe an elimination half-life of about a week, and the tablet label adds that semaglutide remains in the circulation for about five weeks after the last dose. The products differ in their approved uses and in how they are taken, not in how slowly the molecule leaves the body. Ask the prescribing clinician how this applies to your own situation.
Sources
This article is based on the following primary sources. Links open the original documents.
- 1.DailyMed - OZEMPIC- semaglutide injection, solution (Novo Nordisk), section 12.3 Pharmacokinetics · U.S. National Library of Medicine, DailyMed (FDA-approved prescribing information) · accessed
- 2.DailyMed - WEGOVY- semaglutide injection, solution; WEGOVY- semaglutide tablet (Novo Nordisk), sections 5.10 Pulmonary Aspiration, 8.3 Females and Males of Reproductive Potential, and 12.3 Pharmacokinetics · U.S. National Library of Medicine, DailyMed (FDA-approved prescribing information) · accessed
- 3.GLP-1 Receptor Agonists and Endoscopy: Understanding Gastric Stasis, Aspiration Risk, and Contemporary Peri-Procedural Guidance (PMC13393514) · PubMed Central, NIH National Library of Medicine (Chronic Diseases and Translational Medicine, 2026) · accessed
- 4.Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension (PMC9542252) · PubMed Central, NIH National Library of Medicine (Diabetes, Obesity and Metabolism, 2022) · accessed
- 5.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss · U.S. Food and Drug Administration · accessed
- 6.RYBELSUS and OZEMPIC (semaglutide) tablets: prescribing information, section 12.3 Pharmacokinetics · DailyMed, U.S. National Library of Medicine · accessed
- 7.Semaglutide Injection: MedlinePlus Drug Information · MedlinePlus, U.S. National Library of Medicine · accessed
Telehealth prescribing rules differ by state. Read the state-by-state guide.
Majesta Health articles are written against primary sources (FDA labeling, NIH and CDC publications, state statutes) and each one passes a documented compliance review before publication. Where an article cites external sources, they are listed at the end of that article so you can check them yourself. No article currently carries an individual physician review; when a physician reviews an article, that page will show the reviewer's name, NPI and review date.
- Written against primary sources: FDA labeling and safety communications, NIH and CDC publications, state statutes and medical board rules
- Documented compliance review against FDA, FTC and LegitScript requirements before publication
- External sources, where an article cites them, are listed at the end of that article with links to the original documents
- Compounded medications are described as not FDA-approved as final products on every page that mentions them